| |
HIV Specific CAR T Cells in Other study at UCSF (2)
|
| |
| |
Now Deeks and his colleagues have evidence that it can.
Starting in 2020, 10 people with HIV each made about 50 visits to what is known today as Zuckerberg San Francisco General Hospital for an unusually intensive study Deeks designed and led. They received a series of experimental treatments designed to strengthen different parts of their immune response. Then, under close medical supervision, they stopped taking the daily antiretroviral drugs that kept the virus suppressed.
Normally, HIV rebounds within weeks. Seven of the 10 kept the virus under control without treatment. Six maintained low levels for months. In one participant, HIV still hadn't rebounded to detectable levels more than 18 months later, Deeks and his colleagues reported in the journal Nature in December.
A follow-up analysis released in June found signs that the immune system was being mobilized weeks before HIV became detectable again, offering clues to how the treatment may have primed some participants to contain the returning virus. The study was small and lacked a control group, and the treatment remains far too complex for routine use. But the result provides evidence that something Deeks has pursued for decades actually works.
"For the first time ever, we and others are showing that we can meaningfully reshape the immune response to HIV so that it leads to partial control, at least in some people," Deeks says.
https://www.latimes.com/science/story/2026-10-04/at-san-francisco-general-researchers-are-learning-how-to-control-hiv-without-drugs
|
|
| |
| |
|
|
|
